


**Non-Research Determination**

**National Surveillance for Severe Adverse Events Associated with Treatment of  
Latent Tuberculosis Infection  
Extension Request**

**Current OMB No. 0920-0773 Expiring 01/17/2018**

CDC is requesting extension of the currently approved National Surveillance for Severe Adverse Events Associated with Treatment of Latent Tuberculosis Infection (NSSAE) OMB No. 0920-0773 data collection form for the national surveillance system.

We have determined that the information collection is public health surveillance rather than research involving human subjects, thus IRB review and approval are not required. The national tuberculosis surveillance system has been conducted and maintained by the U.S. Public Health Service through the cooperation of the states since 1953. CDC conducts and maintains the system pursuant to the provisions of Section 301(a) of the Public Health Service Act (42 U.S.C. 241) and Section 306 of the Public Health Service Act (42 U.S.C. 241 (a)). Data are protected by an assurance of confidentiality under Section 308(d) of the Public Health Service Act [42 U.S.C. 242m(d)], which prohibits disclosure of any information that could be used to directly or indirectly identify patients.



Benedict I. Truman, MD, MPH  
Associate Director for Science  
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention  
Centers for Disease Control and Prevention

Date: \_\_\_\_\_

5/30/2017



Carla Winston, PhD, MA  
Associate Director for Science  
Division of Tuberculosis Elimination  
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention  
Centers for Disease Control and Prevention

Date: \_\_\_\_\_

5/30/17